Generic Drug Compliance: The Definitive Playbook on IP Risk, Regulatory Enforcement, and Manufacturing Quality
1. Executive Summary and Scope Generic drugs fill 91% of all U.S. prescriptions and generated an estimated $2.44 trillion in […]
Generic Drug Cost Optimization: Cut Production Costs, Win Patent Races, and Dominate the Market
1. Why Cost Structure Is Your Only Durable Weapon The global generic drug market reached approximately $491 billion in 2024.
Generic Drug Market Strategy: The Complete Competitive Playbook
Section 1: The Affordability Paradox: Why the Generic Market Rewards Complexity, Not Cost The generic drug industry has an identity
Generic Drug Market Strategy: The Complete Competitive Playbook Read Post »
What to Look for in a CDMO Contract: What Pharma IP Teams, R&D Leads, and Institutional Investors Actually Need to Know
1. The CDMO Market: Size, Consolidation, and the IP Stakes That Changed Everything The global contract development and manufacturing organization
Biosimilar Regulatory Strategy: The Complete Playbook for FDA, EMA, and Global Approval
A technical deep dive for IP teams, portfolio managers, R&D leads, and institutional investors in biologics and biosimilar development. Why
Biosimilar Regulatory Strategy: The Complete Playbook for FDA, EMA, and Global Approval Read Post »
The Pharmaceutical Patent Strategy Playbook: A Complete Technical Guide for IP Teams, R&D Leads, and Institutional Investors
A single drug can generate $10 billion in annual revenue. The same drug, one day after its last relevant patent
Drug Patent Expirations: The $236 Billion Investment Playbook
“The average branded drug loses roughly 80% of its revenue within 12 months of generic entry. What happens in the
Drug Patent Expirations: The $236 Billion Investment Playbook Read Post »
Inside the Russian Pharma Industry: Key Players and Innovations
Russia’s Drug Machine: Inside the Industry That Rewired Itself Overnight In 2024, the total value of the market reached 2.85
Inside the Russian Pharma Industry: Key Players and Innovations Read Post »
Generic Drugs in Emerging Markets: The $762 Billion Opportunity Pharma Can’t Afford to Miss
How patent cliffs, dual disease burdens, and a rising global middle class are redrawing the map of pharmaceutical competition —
